Author

Rachel Maddux

IMPACT OF OZANIMOD (OZA) ON INTERLEUKIN-17A (IL-17A) LEVELS AND THE ASSOCIATION WITH OZA EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC): RESULTS FROM THE PHASE 3 TRUE NORTH (TN) STUDY
IMPACT OF OZANIMOD (OZA) ON INTERLEUKIN-17A (IL-17A) LEVELS AND THE ASSOCIATION WITH OZA EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC): RESULTS FROM THE PHASE 3 TRUE NORTH (TN) STUDY

Rachel Maddux  et al.

IMPACT OF OZANIMOD (OZA) ON C-REACTIVE PROTEIN (CRP) LEVELS AND THE ASSOCIATION WITH OZA EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC): RESULTS FROM THE PHASE 3 TRUE NORTH (TN) STUDY
IMPACT OF OZANIMOD (OZA) ON C-REACTIVE PROTEIN (CRP) LEVELS AND THE ASSOCIATION WITH OZA EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC): RESULTS FROM THE PHASE 3 TRUE NORTH (TN) STUDY

Rachel Maddux  et al.

ANTI–IL-13 (CENDAKIMAB) ADMINISTRATION IMPROVES OESOPHAGEAL GENE EXPRESSION IN EOSINOPHILIC OESOPHAGITIS
ANTI–IL-13 (CENDAKIMAB) ADMINISTRATION IMPROVES OESOPHAGEAL GENE EXPRESSION IN EOSINOPHILIC OESOPHAGITIS

Rachel Maddux  et al.

ASSOCIATION OF NONSWITCHED MEMORY B-CELL (MBC) LEVELS WITH OZANIMOD (OZA) EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (CD): RESULTS FROM THE PHASE 2 STEPSTONE STUDY
ASSOCIATION OF NONSWITCHED MEMORY B-CELL (MBC) LEVELS WITH OZANIMOD (OZA) EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (CD): RESULTS FROM THE PHASE 2 STEPSTONE STUDY

Rachel Maddux  et al.

Item 1 - 4 / 4
1